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 channels (CaCCs) play an important role in vascular smooth muscle 
contraction. This channel has recently been linked to Pulmonary Arterial Hypertension (PAH) 
due to its significant contribution to vascular tone and remodeling. Evidence shows that CaCCs 
are integral to vascular muscle contraction and could potentially be involved in the enhanced 
vasoconstriction found in PAH patients. TMEM16A is a gene shown to encode for CaCC in 
native pulmonary artery smooth muscle cells (PASMCs). Regulation mediated by CaMKII and 
PIP2 was found to significantly decrease CaCC conductance. This review of literature discusses 
the significance of the regulation of CaCCs in developing new treatments to target PASMCs in 
hypertensive patients. Past research along with future directions of this study could significantly 
contribute to developing novel methods of treatment for Pulmonary Arterial Hypertension, other 
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Pulmonary Arterial Hypertension (PAH) is a chronic cardiovascular disease that 
can be caused by obstruction due to blood clots, vascular remodeling, and an increased 
vasoconstriction in response to agonists in the pulmonary artery (Archer et al., 2010). The 
change in sensitivity and structure of the artery inhibits proper blood flow and causes 
high blood pressure in the pulmonary circulation of the affected individual. Such a 
disease leads to further complications in one’s health and can ultimately lead to death if 
untreated. PAH is rare with an incidence and prevalence rate of approximately 2-50 per 
million (Archer et al., 2010). It is difficult to diagnose and current treatments are both 
inefficient and expensive. Even with treatment after diagnosis, the incidence mortality 
rate is still quite high at 15% in 1 year (Thenappan et al., 2007), thus there is a high 
demand for new treatments to treat the disease. If the regulation of a channel that greatly 
contributes to PAH were fully understood, then perhaps more treatments can be 
developed in the hope of lowering its mortality rate and improving diagnostic criteria.  





 channel (CaCC) conductance was found (Byrne & 
Large, 1987). CaCCs are membrane-spanning ion channels that are widely distributed in 
various cell types. Large & Wang (1996) studied the conductance of CaCCs and 
suggested the channel’s active role in the excitatory mechanism of vascular smooth 
muscle and PASMC’s contractile state.  It is important to study these channels and 
potentially target them for the development of new treatments due to their major role in 
vasoconstriction; one of the main causes of PAH (Archer et al., 2010).  
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 Some information is known about the activation of CaCCs, but the regulation of 
these channels and how they ultimately affect contraction of vascular smooth muscle 
cells (VSMCs) at the molecular level remains elusive. Knowing the molecular 
mechanisms involved in activating and regulating CaCCs can contribute to drug 
development for PAH as well as improving the means for diagnosing the disease.  With 
such a complex channel, various mechanisms have been hypothesized to work together 




currents (ICl(Ca)). Phosphorylation of 
the channel through various enzymes, namely Ca
2+
-Calmodulin Kinase II (CaMKII) 
(Greenwood et. al, 2001), was found to be associated with negative regulation of the 
channel (Angermann et al., 2006; Ayon et al., 2009; Wiwchar et al., 2009). A 
phospholipid, phosphatidylinositol (4,5) bisphosphate (PIP2), was also found to be a 
negative regulator for the channel (Prichard et al., 2014). Both these forms of regulation 
have been studied separately; however, the overall effects of these mechanisms and how 
they interact within the cell have still yet to be identified. 
 This review of literature aims to guide the reader in understanding a complex and 
elusive channel in the context of PAH. It will attempt to answer questions about the role 
of CaCCs in the contractile state of VSMCs and more specifically PASMCs. It will 
define the two main modes of regulation, through CaMKII and PIP2, of CaCCs and how 
regulation of the channel relates back to PAH. Finally, future directions that could be 
taken with this research will be proposed in order to ultimately classify CaCCs as an ideal 







 channels  
 In order to properly understand how the regulation of CaCCs can contribute to 
future studies in drug development for PAH treatment, it is important to understand what 
these channels are and how they function in smooth muscle to elicit contraction. In the 
study of PAH, CaCCs are significant because they are found abundantly throughout the 
membrane of smooth muscle cells (Byrne and Large, 1987). Although, at the time, they 
did not know that Ca
2+
 activated the channel: only that the channel was permeable to Cl
-
. 





smooth muscle cells of rat portal vein directly controlled CaCCs in their gating 
mechanisms. Further investigation indicated that the activation of a Cl
-
 conductance in 
the membrane directly facilitated contraction elicited by Ca
2+
 release from the 
sarcoplasmic reticulum in VSMCs (Kitamura & Yamazaki, 2001). Because patients were 
found to exhibit higher levels of [Ca
2+
]i (Archer et al., 2010), the knowledge that Ca
2+ 
is 
directly involved in CaCC activity underscores the significance of studying this channel 
in the context of PAH. 
CaCCs are quite complex and many mechanisms are involved in their activation 





currents in order to identify the channel’s activity and expression in smooth muscle cells. 
It is also important to know how the channel typically behaves in order to understand 
how adjusting several aspects involved in regulation changes various features of its 
activity. CaCC gating exhibits dependence on [Ca
2+
]i, voltage, and time (Leblanc et al., 
2015). This property accounts for why the channel is considered to be so complex. In 
order to adequately study the channel, one must consider all of the three variables and 
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appropriately control for each of their functions on the channel. CaCCs are also 
characterized as a low conductance channel with recordings of approximately 1-3 pS 
(Klockner, 1993). Knowledge of these key aspects aids future ion channel research by 
helping to identify the presence of classic CaCC conductance on the plasma membrane.  
Mechanism of activation 
Essential to understanding regulation of CaCCs is the knowledge of the 
mechanism that causes the channel to activate. The steps involved in the signal 
transduction pathway inside the cell that leads to a contraction upon stimulation by an 





 channels are anion channels found on the plasma membrane 
(Klockner, 1993). There are various sources of Ca
2+ 
within the cell that cause the opening 
of the channel and Cl
-
 leaving the cell powered by its electrochemical gradient. There is 
an electrical gradient for Cl
-
 caused by the more negative electric charge inside the cell as 
opposed to outside. There is also a higher concentration of Cl
-
 outside the cell, which 
would typically cause Cl
- 
to be pushed into the cell. However, due to the stronger force of 
the electrical gradient pushing the ions outside, the net force will give Cl
-
 the tendency to 
leave the cell when CaCCs open. This efflux of Cl
-
 ions causes the cell to become more 
positive in what is called a depolarization step. The initial depolarization of the cell 
causes voltage-gated Ca
2+
 channels on the plasma membrane to open, further depolarize 
the cell, and elicit a muscle contraction.  
CaCCs, along with Ca
2+
 channels, act in a positive feedback loop mechanism. As 
shown in Figure 1, an agonist (for example, serotonin or otherwise known as 5-HT) binds 
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to a receptor on the plasma membrane. After binding, G-protein coupled receptor 
(GPCR) activity breaks down phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 then acts as a ligand that binds to 
Ca
2+
 channels on the sarcoplasmic reticulum, which causes them to open and release Ca
2+
 
into the cytoplasm. [Ca
2+
]i thus increases and binds to activate CaCCs on the plasma 
membrane. Cl
-
 efflux through CaCCs causes nearby Ca
2+
 channels on the plasma 
membrane to also open and allow Ca
2+
 entry into the cell. [Ca
2+
]i further increases and 
causes more channel activation, which then repeats the cycle (Leblanc et. al, 2015). This 
loop is ongoing, therefore requiring particular mechanisms dedicated to turn CaCCs “off” 
as well as positively regulating them. If no regulatory mechanism were present in this 
pathway, continuous activation would occur and thus lead to ongoing contraction of the 
muscle. In terms of energy utilization, the cell simply cannot afford to be in a constant 
state of contraction. The regulation of CaCCs is a major aspect in the vascular 













Figure 1. Various Sources of Ca
2+
 Activating CaCCs. 1) Agonist stimulates Gq-
protein coupled receptor (Gq-PCR) on plasma membrane; 2) Activated Gq-PCR activates 
Phospholipase C (PLC). PLC breaks down PIP2 into IP3 and DAG; 3) IP3 activates 
ligand-gated Ca
2+
 channel on SR Lumen and causes elevation of Ca
2+ 
in the cytoplasm; 4) 
Intracellular Ca
2+
 binds to ANO1 and opens channel. Cl
-
 efflux due to electrochemical 
gradient; 5) Depolarization caused by Cl
-
 efflux triggers activation in voltage-gated Ca
2+ 
on plasma membrane and elicits Ca
2+ 
entry. This further depolarizes the cell and causes 
muscle contraction; 6) Ca
2+
 levels increase and cause opening of more ANO1 channels 




 channels to open in SR Lumen and 




Molecular Identity of Ca2+-activated Cl- channels  
For years, it was quite difficult to conduct research on CaCCs due to multiple 
reasons: a lack of efficient pharmacological agents that would properly block or activate 
the cell, the sheer complexity of the cell in its different types and activation modes, and 
most significantly, the lack of information of its exact molecular identity (Leblanc et al., 
2015). Several genes, such as Bestrophin (Sun et al., 2002), were initially postulated to 
encode for the channels in question; however, those genes did not prove to be the best 
molecular candidate. It was recently found in three independent studies that TMEM16 or 
Anoctamin (ANO), a family of plasma membrane proteins, encodes for CaCCs in various 
cell types (Caputo et al., 2008; Schroeder et al., 2008; Yang et al., 2008). With the 
channel’s exact function previously unknown, the three studies identifying the 
relationship between TMEM16/ANO and CaCCs significantly advanced the progression 
of research in these target channels. Anoctamins became the most promising candidate 
for the channel’s genetic identity due the observation that its elicited current had a very 
similar pattern of activity with the ICl(Ca) generated in native smooth muscle cells. Of the 





channels (Schreiber et al., 2010). Although researchers were able to breed and develop 
mice with the ANO2 gene knocked out (Billig et al., 2011), they encountered some 
difficulty in studying ANO1 knockout mice due to death within 30 days after birth (Rock 
et al., 2008). When ANO1 was knocked out in mice, the embryos did not survive due to 
improper formation of their airways during development. Due to this setback, it was 
difficult for scientists to properly study ANO1 in vivo. A few studies previously 
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conducted point to ANO1 as the main pore-forming subunit of CaCC due to the fact that 
greater levels of transcript were reported for ANO1 compared to ANO2 (Davis et al., 
2010; Manoury et al., 2010; Thomas-Gatewood et al., 2011). Therefore, it is reasonable 
to consider TMEM16A/ANO1 as the model molecular identity of CaCC for this study.  
The discovery of the gene encoding CaCCs was paramount in research involving 
the ion channel in PASMCs. With the knowledge of what encodes for the channel found 
in PASMCs, researchers were able to overexpress the gene in other cells. This is 
beneficial in a number of ways. Mainly, cell lines can be used in experiments instead of 
fresh isolation of PASMCs. Namely, Human Embryonic Kidney 293 (HEK 293) cells can 
be grown very easily in culture and transfected with the desired plasmid: in this case, 
TMEM16A. After transfection, the HEK 293 cells would have overexpressed the channel 
and thus allowing for easier measurement of conductance. In native PASMCs, many 
channels are present on the plasma membrane at relatively equal rates, thus making it 
difficult to isolate the CaCC conductance from the rest. With the identification of the 
molecular identity of CaCC, TMEM16A can be overexpressed in HEK 293 cells and thus 
resolving that issue.  
The activation and the molecular identity of CaCCs are very important due to the 
fact that they can be applied to further studies of TMEM16A/ANO1 in the context of 
their role in PAH. Having the background information on the activation mechanism of 
ANO1 is integral to studying its regulation and the aspects that can cause the channel to 
potentially become more activated in PAH. Knowing the gene encoding the target 
channel is essential to furthering research and allowing for more efficient techniques to 
be used in experiments.  
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Significance of CaCCs in Pulmonary Arterial Hypertension 
Pulmonary Arterial Hypertension 
 Pulmonary Arterial Hypertension is a cardiovascular disease in which obstruction 
in the pulmonary artery causes an increase in pulmonary vascular resistance (PVR). This 
increase over time leads to right ventricular failure. Heart failure occurs due to the extra 
effort that the right ventricle has to apply in order to properly pump deoxygenated blood 
through the pulmonary artery to the lungs (Figure 2).  
 
Figure 2. Diagram Displaying Effects of Pulmonary Arterial Hypertension. A normal 
heart is depicted on the left and a heart with PAH is on the right. Patients with PAH will 
exhibit an increase in pulmonary vascular resistance due to thickening of the pulmonary 
arterial wall. Normal pulmonary artery pressure (PAP) is shown on the bottom as well as 
varying degrees of PAH. Pulmonary capillary wedge pressure (PCWP) for normal and 





PAH is quite rare with an incidence and prevalence rate of 2-5 per million in 
Europe and the United States (Archer et al., 2010). In order to accurately diagnose PAH, 
physicians will need to perform a right heart catheterization (RHC) through the 
pulmonary artery in order to measure the resting mean pulmonary artery pressure (PAP), 
pulmonary vascular resistance (PVR), and normal pulmonary capillary wedge pressure 
(PCWP) (Montani et al., 2013). PAH is defined by a PAP ≥ 25 mmHg, PVR > 3 Wood 
units, and a PCWP < 15 mmHg (Archer et al., 2010). The low incidence rate is likely 
caused by the fact that RHC, an invasive procedure, is needed to properly diagnose PAH. 
Especially in underdeveloped countries, where healthcare is not as accessible, it is 
presumably less likely for a PAH patient to receive a diagnosis. For this reason, if 
scientists and physicians had a better understanding of channels that directly impact 
PASMCs and cause enhanced vasoconstriction, better diagnostic techniques may be 
developed. More efficient means of diagnosis could potentially lead to catching the 
disease early on and possibly lowering its high mortality rate of 15% every year (Archer 
et al., 2010). Depending on the comorbidity of other associated conditions, the 3-year 
survival rates of PAH varies between 34-77% (Archer et al., 2010). Such a high number 
could be decreased if treatment for PAH were given in the earlier stages of the disease. 
 Treatment for PAH is crucial upon prognosis; however, those treatments are 
difficult to administer and are more palliative than curative. Various treatments that target 
different aspects of the disease are available for patients (Table 1). The main treatments 
currently used are prostanoids, endothelin receptor blockers, and phosphodiesterase 5 
inhibitors (Archer et al., 2010).  Therapies are also quite costly: expenses depending on 
the patient’s treatments can range up to over $90,000/year (Archer et al., 2010). Knowing 
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this information, it becomes clear why there is a high demand for further pharmacological 
research in order to develop more efficient and less expensive treatments. 
Role of TMEM16A/ANO1 in Pulmonary Hypertension 
 Research recently conducted has proposed that CaCCs could be involved in 
pulmonary (Sun et al. 2012; Forrest et al., 2012) as well as systemic (Wang et al., 2012; 
Heinze et al., 2014) hypertension. In studying animal models of PAH, it appears that 
PASMCs are more depolarized and exhibit higher levels of [Ca
2+
]i (Archer et al., 2010). 
Because TMEM16A is mainly controlled by [Ca
2+
]i, researchers hypothesized a 
correlation between CaCCs and PAH. This hypothesis was supported by Sun et al. (2012) 
and Forrest et al. (2012) in their studies on two distinct models of pulmonary 
hypertension (PH) in the rat. The elevated activity of CaCCs in PA smooth muscle cells 
was shown to be a major contributor to pulmonary hypertension.  Similarly, the alteration 
of TMEM16A has been thought to play a role in cerebrovascular remodeling, which has 
been associated with hypertension and increased risk of stroke. Upon studying the 
influence of CaCCs on hypertension in basilar smooth muscle cells, Wang et al. (2012) 
found that these ion channels down regulate cell proliferation. PAH patients were also 
found to have elevated levels of serotonin (5-HT) (Herve et al., 1995). As shown in 
Figure 1, vasoconstriction in PASMCs occurs after an agonist elicits a signal transduction 
pathway in the cell. Higher levels of serotonin could cause elevated activation of the 
channel and thus excessive vasoconstriction. Due to the major role of ANO1 in the 
excitatory mechanism of PASMCs, it is likely to also be associated with abnormal cell 
activity observed in PAH patients.  
12 
 
Specifically two groups found that there was, in fact, an increase in CaCC activity 
and ANO1 expression of the pulmonary arteries in two models of pulmonary 
hypertension in the rat: monocrotaline (Forrest et al., 2012) and chronic hypoxia (Sun et 
al., 2012). In both studies, CaCC current density was elevated approximately two-fold in 
the PASMCs of rats with pulmonary hypertension. This elevation was observed alongside 
a similar pattern of increase found in the expression of ANO1 in mRNA and protein. 
Interestingly, not only was this pattern acknowledged in models of pulmonary 
hypertension, but a similar increase in ANO1 expression was also found in asthma 
(Zhang et al., 2013) and some forms of cancer (Hartzell et al., 2009). This emphasizes the 
importance of this study not only on the role of CaCCs for the discovery of new 
therapeutic targets for hypertension, but potentially for other common debilitating 
diseases.  
CaCCs have previously been associated with cerebrovascular remodeling in 
basilar artery smooth muscle cells in hypertensive rats (Wang et. al, 2012). This relation 
therefore makes the study of the channel significant in the search for new treatments of 
PAH. Recent studies, including one from Dr. Leblanc’s group (2015), have also 
implicated CaCCs in contributing to the enhanced vasoconstriction observed in two 
animal models of pulmonary hypertension (Sun et al., 2012; Forrest et al., 2012). 
Studying how we may be able to negatively regulate ICl(Ca) in these myocytes will greatly 
improve the understanding of the role of these channels in dysfunctional blood pressure 
regulation and arterial remodeling in cardiovascular diseases. Further research could have 
a significant impact on pharmacological improvement in the treatment of heart conditions 
as well as diseases associated with cell proliferation like cancer.  
13 
 
Pharmacology and Regulation of CaCCs in smooth muscle cells 
The study of how CaCCs are regulated started off slow and inconclusive. 
Researchers identified various drugs such as anthracene-9-carboxylic acid, furosemide, 
and many others that all played a role in blocking or activating the channels (Leblanc et 
al., 2015), but most were considered inefficient and not specific enough to the targeted 
channel. Of those drugs, scientists found niflumic acid (NFA) to be the most effective 
blocker of these channels (Large & Wang, 1996) so NFA has been most used in studying 
CaCCs in physiological settings. Currently, scientists rely on the ability of blockers to 
reduce vasoconstriction to assess the role of CaCCs in PASMCs. However, regulation of 
these channels could also be hypothesized as an ideal therapeutic target in modulating 
ANO1 in disease states.  
Regulation by phosphorylation 
Studies have previously identified the significance of phosphorylation on the 
regulation of CaCCs in smooth muscle (Angermann et al., 2006; Wiwchar et al., 2009). 
Wang & Kotlikoff (1997) first showed how CaMKII activity caused a decrease in CaCC 
activity in tracheal smooth muscle cells. They suggested that CaCCs were inactivated by 
CaMKII-mediated phosphorylation based on the observation that ICl(Ca) declined slower in 
the experimental group than in wild type. One of the experimental groups consisted in 
blocking CaMKII with a specific inhibitor. After inhibition, the CaCC current and [Ca
2+
]i 
declined at the same rate. Without the blocker or wild type, the current declined faster 
than [Ca
2+
]i,  which they attributed to a phosphorylation-induced current inactivation. 
They attributed this down regulating effect to CaMKII-induced phosphorylation or a 
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regulatory subunit associated with the protein. Further research indicated that CaCC 
activity in rabbit pulmonary (PA) and coronary artery (CA) smooth muscle is also down 





 currents by kinase activity implies that CaCCs are also 
regulated by at least one phosphatase such as Calcineurin (CaN) or protein phosphatase 
1/protein phosphatase 2A (PP1/PP2A) (Ledoux et al., 2003).  
Studies were conducted examining the possible involvement of CaMKII, CaN, 
and PP1/PP2A in regulatory mechanisms. As seen in Figure 3, Calcineurin, a 
serine/threonine phosphatase activated by Ca
2+
, was found to stimulate CaCCs by 
dephosphorylating the pore-forming of a regulatory subunit of the channel (Greenwood et 
al., 2004) and enhance CaCC activity in smooth muscle cells by increasing its sensitivity 
to [Ca
2+
]i (Ledoux et al., 2003). CaN, therefore, acts as an antagonist for the effects of 
CaMKII. Ayon et al. (2009) identified two additional serine/threonine phosphatases, 
(PP1/PP2A), that were also shown to up regulate ICl(Ca) in rabbit PA smooth muscle cells. 
Their study also observed an interaction between PP1/PP2A and CaN Aα where 
PP1/PP2A is downstream of CaN in the regulation pathway. As much as the exact 
identity of the enzyme and its binding mechanism is unknown, the signaling pathway of 
these regulatory enzymes remains just as elusive. Researchers are uncertain if the 
enzymes in question either directly regulate the pore forming or if they act as second 




Figure 3. Diagram of Hypothesized Regulatory Pathway in CaCCs by 
Phosphorylation. CaCCs activation is modulated by CaMKII upon [Ca
2+
]i increase in 
the cell. CaN and PP1/PP2A act as antagonists to the inhibitory effect of CaMKII on the 
channel (Ayon et al., 2009).  
Negative regulation by PIP2 
PIP2 is a phospholipid found in plasma membranes known to regulate various ion 
channels (Suh & Hille, 2008). For a while, there was no evidence to confirm the role of 
PIP2 in regulating TMEM16A. Pritchard et al. (2014) conducted several experiments on 
isolated PASMCs of rats as well as on HEK 293 cells overexpressing TMEM16A. 
Through various techniques such as Western blot, immunoprecipitation, dot blots, lipid 
assay, and patch clamp, researchers were able to identify PIP2 as a negative regulator of 
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the channel. They found that in the absence of an agonist or when [Ca
2+
]i  is low (resting 
state – 100 nM), PIP2 is bound to the channel and contributing to its closed state. 
Activation of the channel is caused by the stimulation of Phospholipase C (PLC), which 
breaks down PIP2 into two components, DAG and IP3. IP3 binds to a Ca
2+
 receptor on the 
sarcoplasmic reticulum and thus allows for the release of Ca
2+
 and elevation of [Ca
2+
]i 
that opens ANO1. 
Wortmannin is a drug known to decrease PIP2 levels (Saleh et. al, 2009). 
Wortmannin acts by directly inhibiting PI4K, which is required for PIP2 re-synthesis as 
well as the depletion of PIP2 levels within the cell. Rat PASMCs and transfected HEK 
293 cells were previously pretreated with Wortmannin and incubated for 1 hour before 
ICl(Ca) was recorded (Pritchard et. al, 2014). That set of experiments allowed the 
investigators to conclude that the inhibition of PIP2 increases ICl(Ca) and this was 
consistent with the hypothesis that PIP2 negatively regulates ANO1. However, it is 
natural to wonder if these same results can be found immediately after the same amount 
of Wortmannin (20 microM) is presented to the cell under whole cell patch clamp. The 
question of the time required to see these suggested effects is the basis of this thesis.  
 Research so far suggests that varying ATP levels, phosphorylation, and the 
presence of PIP2 all play a role in regulating CaCCs. Although great lengths have been 
achieved to propose many possible mechanisms to regulate TMEM16A/ANO1, more 










 channels. Studies on this channel have significantly contributed to the argument that 
CaCCs should be considered as a novel therapeutic target for treatment of PAH. CaCC 
activity has been shown to contribute to enhanced vasoconstriction animal models of 
PAH (Leblanc et al., 2015).  CaCCs have been studied for many years due to their 
presence in smooth muscle cells. Much progress has definitely been made in the past 
decade alone. Because of the research carried out so far, it was shown that CaCCs do 
contribute to vasoconstriction and their inhibition (using pharmaceutical means) 
significantly attenuates smooth muscle activity. We know that TMEM16A/ANO1 
encodes for these channels and demonstrate similar patterns in activity. The mechanisms 
of activation for CaCCs and how they affect [Ca
2+
]i have also become better understood. 
It is now known that there is a positive feedback loop mechanism that occurs in the 
activation of the channel. Research has also shown that CaMKII as well as PIP2 regulate 
ANO1. The major role of TMEM16A in PASMCs and the fact that activity can be 
regulated in cells makes this channel a good possible candidate for treatment studies 
regarding PAH.  
After further questions about CaCCs have been investigated and answered, it 
could change the direction of ways to treat Pulmonary Arterial Hypertension. The 
development of new drugs that specifically target this channel and therefore regulate it 
could greatly reduce the expense and increase the efficiency of the treatment of this 
disease. This research not only could affect the pharmaceutical side of PAH, but the 
diagnosis of the disease as well. Perhaps, if more information was known about CaCCs 
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and how they function, it may be easier for clinicians to detect and accurately treat it. 
Especially in underdeveloped countries, where healthcare is not as accessible, research in 
PAH could provide more awareness and earlier diagnosis of this disease. This could 
mean earlier treatment for PAH patients and thus ultimately reducing the global 
morbidity rates of the disease. CaCCs have also been implicated in cell proliferation 
mechanisms, which is a key aspect of diseases such as cancer. Not only that, but CaCCs 
are found in a wide variety of cells outside the cardiovascular system such as the 
epithelial cells, neuronal cells, and skeletal muscle, just to name a few (Hartzell, 2005). A 
better understanding of CaCCs, on how it functions and is regulated, could not only 





With the information outlined in this review of the literature, many future 
directions in research could be suggested: 1) How does ANO1 directly affect membrane 
depolarization in PASMCs? 2) What is the exact mechanism of regulation by CaMKII 
phosphorylation? 3) What is the molecular mechanism of regulation by PIP2 on the 
channel activity? 4) Is there an interaction between the signaling pathways, CaMKII and 
PIP2, which leads to down-regulation of ANO1?  
These potential studies could further define regulation in ANO1 and could 
potentially aid drug development in PAH as well as other diseases related to cells 
expressing CaCC activity.  
How does ANO1 directly affect membrane depolarization in PASMCs? 
 In the past, researchers have relied on ANO1 inhibition using drugs in order to 
study CaCC activity in PASMCs. This was due to the fact that mice in which ANO1 was 
globally knocked out would not survive long enough to be studied. A possible study 
would be to successfully knock out the gene and study CaCC inhibition on freshly 
isolated smooth muscle cells. To do this, an inducible knockdown could be elicited in 
mice at a specific tissue for a specific gene at any stage of their development. This 
technique is very innovative in that studies exploring ANO1 knockdown in mice at any 
stage of their life can be conducted. These experiments could give us a clearer image of 
conductance observed in native PASMCs after ANO1 is knocked down and there is less 
expression of CaCCs. 
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What is the exact mechanism of regulation by CaMKII phosphorylation? 
 It is evident that CaMKII mediates CaCC activity by phosphorylation. The 
positive feedback loop mechanism associated with the depolarization of voltage-gated 
Ca
2+
 channels and further activation of ANO1 is controlled by CaMKII activity. It has 
also been suggested that CaN and PP1/PP2A play a role in this regulation mechanisms. 
However, it is unclear exactly how these proteins operate at the molecular level. Do they 
act through a secondary messenger that binds to the channel or do they regulate it 
directly?  
 The structure of TMEM16A (Figure 4) shows serine-threonine residues on the 
cytoplasmic portion of the plasma membrane. CaMKII, a serine-threonine phosphatase, 
likely binds to these residues and causes down-regulation of the channel. To tackle this 
problem, those residues could be mutated Alanine, a neutral amino acid that will not 
affect the way the protein folds originally. This is important in order to ensure that any 
effects in channel conductance is strictly associated with the change in amino acid and 




Figure 4. Proposed structure for TMEM16A/ANO1 and possible CaMKII binding 




What is the molecular mechanism of regulation by PIP2 on the channel activity? 
 We now know that PIP2 inhibits ANO1 under un-stimulated conditions by 
directly binding to it. However, it is unclear to which domain PIP2 binds to, and how 
changes in the concentration of PIP2 at the membrane directly impacts CaCC 
conductance. This could further understanding of how PIP2 levels can best be regulated in 
order to appropriately down-regulate the channel.  Site-directed mutagenesis, deletion of 
a gene segment, can be done on ANO1 in order to test for where the molecule binds. The 
binding sites are composed of Arginine and Lysine residues that can be mutated to 
Alanine, a neutral amino acid. Figure 5 shows the suggested binding sites of PIP2 on the 
channel and so experiments can be done to mutate those sites and observe the effects it 
has on conductance.  
 
Figure 5. Proposed binding sites of PIP2 and TMEM16A sequence. A) Potential 
binding domains of PIP2 onto the transmembrane protein channel. B) TMEM16A 




Is there an interaction between the signaling pathways, CaMKII and PIP2, which 
leads to down-regulation of ANO1?  
 A very important direction to take with future studies of CaCCs is the combined 
role of CaMKII and PIP2 in regulating the channel. It is known how each pathway affects 
the channel’s activity separately, but it will be important to understand how the two 
pathways interact with each other. Is there some communication between them at the 
molecular level? 
 Tubby is a transcription factor that can be used to report PIP2 levels in the cell 
(Quinn et al., 2008). It specifically binds to PIP2 and can be detected using total internal 
reflection fluorescence microscopy (TIRFM). Phosphorylation can be studied 
concurrently by using the whole-cell patch clamp technique (Figure 6). Studies conducted 
can be a simultaneous imaging of regulation by PIP2 after channel is run down due to 
phosphorylation by CaMKII or when phosphorylation is inhibited by phosphatases such 
as CaN or PP1/PP2A. Exploring the interactions between these two key modes of 
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Figure 6. Whole-cell Patch Clamp Diagram. Pipette is brought down to cell membrane 
and suction is applied. After the seal secured between the pipette and membrane, more 






Table 1. List of treatments for Pulmonary Arterial Hypertension. Treatments 
available for PAH listed by the structure they target, their function, the type of drug, and 
if they are used in humans (Archer et al., 2010).  
 
 
